Scarica l'app Stockscreener
0.721
1.11%
0.0079
Dopo l'orario di chiusura:
.72
-0.001
-0.14%
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Dare Bioscience (DARE) Secures $908K NIH Grant Amidst Challengin - GuruFocus
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com Nigeria
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth - Barchart.com
Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold - Stock Titan
Dare Bioscience Inc (DARE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Barchart.com
IPO Databook: Daré Bioscience (DARE US)Aug 2026 - smartkarma.com
Daré Bioscience publishes sildenafil cream study results - Investing.com
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Barchart.com
A women’s health biotech launches one product while preparing another to generate revenue - Stock Titan
L1 Capital caps Dare Bioscience (DARE) stake at 9.99% - Stock Titan
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - sahmcapital.com
Forbes puts a women's health biotech CEO on its 2026 innovation list - Stock Titan
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: C - GuruFocus
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Form 8K Dare Bioscience Inc For: 17 August By Investing.com - Investing.com Nigeria
Daré Bioscience Raises ~$6 Million in Equity Offering at $1.37 With Attached Warrants - TradingView
H.C. Wainwright reiterates Dare Bioscience stock rating at buy By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Q2 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Daré Bioscience raises $6M in registered direct offering By Investing.com - Investing.com India
Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall - marketscreener.com
Daré Bioscience raises $6M in registered direct offering - Investing.com
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement - moomoo.com
Daré Bioscience Announces Pricing of $6.0 Million - GlobeNewswire
Daré Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Dare Bioscience earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Daré Bioscience (DARE) Launches New Product Amid Challenging Val - GuruFocus
Dare Bioscience (DARE) Q2 Results Highlight Challenges Amid Low Valuation on Price-to-Sales Basis - GuruFocus
Daré Bioscience launches Flora Sync LF5 for direct revenue - scanx.trade
Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours - Investing.com
Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline - TradingView
Dare Bioscience Q2 Results: Net loss narrows to $3.0M, cash falls - scanx.trade
Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary - TradingView
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances - The Manila Times
Daré Bioscience launches Flora Sync, its first directly commercialized product - Stock Titan
Dare Bioscience reports Q2 2026: $0.19M revenue, $2.98M net loss, cash $12.6M - TradingView
Dare Bioscience Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Transcript : Daré Bioscience, Inc.Special Call - marketscreener.com
Women keep recommending £20 gynaecologist-backed dryness buy that sold out 5 times - AOL.co.uk
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience (DARE.US) will release its earnings report after market close on August 13. - Moomoo
Dare Bioscience (DARE) Eases 0.75% to $1.33: Stock Hovers Between Key Support and ResistanceHedge Fund Exposure - dars.gov.et
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 - The Manila Times
Daré Bioscience to Host Second Quarter 2026 Financial - globenewswire.com
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Darling: Q2 Earnings Snapshot - AOL.com
Dare Bioscience Expands Access Options for DARE to PLAY and Specialized Menopause Care through Strategic Collaboration with MyMenopauseRx - marketscreener.com
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Slides on MyMenopauseRx Hookup - Baystreet.ca
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):